APO Research
Talk to an analyst

APO RESEARCH · REPORT

Duchenne Muscular Dystrophy (DMD) Therapeutics

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Selected research

Market Analysis & Forecast

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast 2026-2032

27 December 2025199 pages

Choose your research edition.

Industry ResearchDuchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

By region, North America has the highest market share, reaching 70.66% in 2019.

Sarepta Therapeutics and PTC Therapeutics hold amlost the whole market.

Read the full market overview

Report Includes

This report presents an overview of global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Duchenne Muscular Dystrophy (DMD) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Duchenne Muscular Dystrophy (DMD) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Company

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type

Exondys

Emflaza

Translarna

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals

Clinics

Home Care

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy (DMD) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Exondys Major Player Table 3. Emflaza Major Player Table 4. Translarna Major Player Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospitals Major Player Table 7. Clinics Major Player Table 8. Home Care Major Player Table 9. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends Table 10. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers Table 11. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges Table 12. Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints Table 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2021-2026) Table 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region (2027-2032) Table 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2021-2026) Table 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Headquarters & Area Served Table 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Product Type & Application Table 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Duchenne Muscular Dystrophy (DMD) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2021-2026) Table 30. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2027-2032) Table 31. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021-2026) Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2027-2032) Table 36. Sarepta Therapeutics Company Information Table 37. Sarepta Therapeutics Business Overview Table 38. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 40. Sarepta Therapeutics Recent Development Table 41. PTC Therapeutics Company Information Table 42. PTC Therapeutics Business Overview Table 43. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 45. PTC Therapeutics Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 50. Pfizer Recent Development Table 51. Bristol-Myers Squibb Company Information Table 52. Bristol-Myers Squibb Business Overview Table 53. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 55. Bristol-Myers Squibb Recent Development Table 56. Italfarmaco Company Information Table 57. Italfarmaco Business Overview Table 58. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 60. Italfarmaco Recent Development Table 61. Santhera Pharmaceuticals Company Information Table 62. Santhera Pharmaceuticals Business Overview Table 63. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio Table 65. Santhera Pharmaceuticals Recent Development Table 66. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 67. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 68. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 69. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 70. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 71. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 72. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 73. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 74. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 75. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 76. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 77. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 78. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 79. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 80. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 81. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 82. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 83. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 84. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 85. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 86. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 87. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 88. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 90. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 91. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 92. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 93. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 94. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 95. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 97. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Image Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Exondys Image Figure 5. Emflaza Image Figure 6. Translarna Image Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospitals Image Figure 10. Clinics Image Figure 11. Home Care Image Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2021-2032) Figure 20. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021-2032) Figure 23. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032) Figure 25. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032) Figure 26. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Country (2021-2032) Figure 27. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032) Figure 32. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032) Figure 33. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Country (2021-2032) Figure 34. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032) Figure 44. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032) Figure 45. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032) Figure 47. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032) Figure 48. Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Region (2021-2032) Figure 49. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032) Figure 57. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032) Figure 58. SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Country (2021-2032) Figure 59. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Exondys
  • Emflaza
  • Translarna
Applications
  • Hospitals
  • Clinics
  • Home Care
Companies covered
  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type
  3. 1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Exondys
  5. 1.2.3 Emflaza
  6. 1.2.4 Translarna
  7. 1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
  8. 1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospitals
  10. 1.3.3 Clinics
  11. 1.3.4 Home Care
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
  1. 2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
  2. 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Drivers
  3. 2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players
  2. 4.1.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Product Type & Application
  8. 4.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Duchenne Muscular Dystrophy (DMD) Therapeutics Tier 1, Tier 2, and Tier 3
5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
  1. 5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type (2021-2032)
6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
  1. 6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sarepta Therapeutics
  2. 7.1.1 Sarepta Therapeutics Company Information
  3. 7.1.2 Sarepta Therapeutics Business Overview
  4. 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  6. 7.1.5 Sarepta Therapeutics Recent Developments
  7. 7.2 PTC Therapeutics
  8. 7.2.1 PTC Therapeutics Company Information
  9. 7.2.2 PTC Therapeutics Business Overview
  10. 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  12. 7.2.5 PTC Therapeutics Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Italfarmaco
  26. 7.5.1 Italfarmaco Company Information
  27. 7.5.2 Italfarmaco Business Overview
  28. 7.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  30. 7.5.5 Italfarmaco Recent Developments
  31. 7.6 Santhera Pharmaceuticals
  32. 7.6.1 Santhera Pharmaceuticals Company Information
  33. 7.6.2 Santhera Pharmaceuticals Business Overview
  34. 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
  36. 7.6.5 Santhera Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country
  11. 8.6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country
  11. 9.6.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2021-2032)
  2. 10.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country
  11. 11.6.1 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst